Drugs / PHE885
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04318327 | Jul 2020 → Apr 2025 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05172596 | Mar 2022 → May 2025 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-12-13 | Novartis Pharmaceuticals | Results Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 novartis.com ↗
Initial efficacy results include 73% complete response rate at month three with dose level two in the YTB323 study in DLBCL and 100% best overall response in the PHE885 study in multiple myeloma 1,2 |
| 2021-12-02 | Novartis Pharmaceuticals | Results Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms novartis.com ↗
In first-in-human trials to be presented at ASH 2021, lead candidates YTB323 and PHE885 showed 75% Complete Response in Diffuse Large B-Cell Lymphoma (DLBCL) at three months and 100% Best Overall Response (BOR) in multiple myeloma, respectively. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-13 | Novartis Pharmaceuticals | Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 novartis.com ↗ |
| 2021-12-02 | Novartis Pharmaceuticals | Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHE885 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318327 ↗ |
| Modality | Cell therapy | “autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR)” NCT04318327 ↗ |
| Route | Other | “Infusion” NCT04318327 ↗ |